Compass Therapeutics (CMPX) Stock Price, News & Analysis

-0.04 (-2.63%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
147,772 shs
Average Volume
337,270 shs
Market Capitalization
$203.63 million
P/E Ratio
Dividend Yield
Price Target

Compass Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
508.1% Upside
$9.00 Price Target
Short Interest
1.97% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($0.48) to ($0.50) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.55 out of 5 stars

Medical Sector

441st out of 907 stocks

Biological Products, Except Diagnostic Industry

66th out of 154 stocks

CMPX stock logo

About Compass Therapeutics Stock (NASDAQ:CMPX)

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

CMPX Stock Price History

CMPX Stock News Headlines

Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
Compass Therapeutics Inc Ordinary Shares
Compass Therapeutics Provides Corporate Update
Compass Therapeutics Insider Ups Holding During Year
TD Cowen Keeps Their Buy Rating on COMPASS Pathways (CMPS)
See More Headlines
Receive CMPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.17 per share


Free Float
Market Cap
$203.63 million
Not Optionable
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Vered Bisker-Leib M.D. (Age 52)
    MBA, Ph.D., Chief Executive Officer
    Comp: $806.43k
  • Dr. Thomas J. Schuetz M.D. (Age 63)
    Ph.D., Co-Founder, President of Research & Development and Vice Chair
    Comp: $829.56k
  • Mr. Neil L. Lerner CPA (Age 57)
    Vice President of Finance
  • Mr. Jonathan Anderman J.D.
    VP, Head of Legal & Corporate Secretary
  • Anna Gifford
    Communications Manager
  • Dr. Minori Rosales M.D. (Age 61)
    Ph.D., Senior VP & Head of Clinical Development
  • Ms. Karin Herrera B.A.
    VP & Head of Clinical Operations
  • Dr. James Kranz Ph.D.
    VP and Head of Chemistry Manufacturing & Controls

CMPX Stock Analysis - Frequently Asked Questions

Should I buy or sell Compass Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compass Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMPX shares.
View CMPX analyst ratings
or view top-rated stocks.

What is Compass Therapeutics' stock price target for 2024?

2 Wall Street analysts have issued 1 year price objectives for Compass Therapeutics' shares. Their CMPX share price targets range from $8.00 to $10.00. On average, they predict the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 508.1% from the stock's current price.
View analysts price targets for CMPX
or view top-rated stocks among Wall Street analysts.

How have CMPX shares performed in 2024?

Compass Therapeutics' stock was trading at $1.56 at the start of the year. Since then, CMPX stock has decreased by 5.1% and is now trading at $1.48.
View the best growth stocks for 2024 here

Are investors shorting Compass Therapeutics?

Compass Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 1,620,000 shares, a decrease of 13.8% from the March 15th total of 1,880,000 shares. Based on an average daily volume of 485,500 shares, the days-to-cover ratio is currently 3.3 days. Approximately 2.0% of the shares of the company are short sold.
View Compass Therapeutics' Short Interest

When is Compass Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CMPX earnings forecast

How were Compass Therapeutics' earnings last quarter?

Compass Therapeutics, Inc. (NASDAQ:CMPX) issued its quarterly earnings results on Thursday, March, 21st. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02.

When did Compass Therapeutics IPO?

Compass Therapeutics (CMPX) raised $50 million in an initial public offering on the week of November 16th 2020. The company issued 9,000,000 shares at a price of $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager.

Who are Compass Therapeutics' major shareholders?

Compass Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Simplicity Wealth LLC (0.03%). Insiders that own company stock include Carl L Gordon, Orbimed Advisors Llc, Thomas J Schuetz and Vered Bisker-Leib.
View institutional ownership trends

How do I buy shares of Compass Therapeutics?

Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CMPX) was last updated on 4/25/2024 by Staff

From Our Partners